Search company, investor...


Founded Year




Total Raised


Date of IPO


About Ambrx

Ambrx (NYSE: AMAM) is a clinical-stage biotechnology company focused on discovering and developing first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates. The company's proprietary technology platforms enable the attachment of pharmaceutically active molecules to specific sites within proteins more precisely than prior generations of bio-conjugates and with precision similar to that used to design small-molecule drugs. Ambrx has developed a pipeline of novel product candidates that include antibody-drug conjugates, or ADCs, bi- and multi-specific drug conjugates, and long-acting therapeutic proteins.

Headquarters Location

10975 North Torrey Pines Road

La Jolla, California, 92037,

United States


Missing: Ambrx's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ambrx's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Ambrx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ambrx is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Ambrx Patents

Ambrx has filed 121 patents.

The 3 most popular patent topics include:

  • G protein coupled receptors
  • Immunology
  • Monoclonal antibodies
patents chart

Application Date

Grant Date


Related Topics




Diabetes, Clusters of differentiation, Androgens and anabolic steroids, Androstanes, Animal virology


Application Date


Grant Date



Related Topics

Diabetes, Clusters of differentiation, Androgens and anabolic steroids, Androstanes, Animal virology



Latest Ambrx News

Ambrx Biopharma to launch ~$75M registered direct offering

May 24, 2023

tupungato Ambrx Biopharma (NASDAQ: AMAM ) is set to sell ~5.4M American Depositary Shares at $13.93 per ADS in an ~$75M registered direct offering. The biopharmaceutical company has entered into a securities purchase agreement with clients managed by Darwin Global Management. Darwin has agreed not to sell any securities for 6 months following the closing of the offering. The offering is expected to close on or around June 30. The proceeds are intended to be used to fund the research and development of its product candidates, and for working capital and general corporate purposes. AMAM shares were trading -4.78% pre-market.

Ambrx Frequently Asked Questions (FAQ)

  • When was Ambrx founded?

    Ambrx was founded in 2003.

  • Where is Ambrx's headquarters?

    Ambrx's headquarters is located at 10975 North Torrey Pines Road, La Jolla.

  • What is Ambrx's latest funding round?

    Ambrx's latest funding round is IPO.

  • How much did Ambrx raise?

    Ambrx raised a total of $373.8M.

  • Who are the investors of Ambrx?

    Investors of Ambrx include HBM Healthcare Investments, Invus Group, Fidelity Investments, BlackRock, Suvretta Capital Management and 31 more.

  • Who are Ambrx's competitors?

    Competitors of Ambrx include Cevec Pharmaceuticals, Asieris Pharma, AbSci, ImmunoReagents, Sutro Biopharma, InflaRx, Molecular Templates, Merus, Glaukos, Nps Pharmaceuticals and 22 more.

Compare Ambrx to Competitors


Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute ( and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).

Harkness Pharmaceuticals

Harkness Pharmaceuticals is focused on developing anti-obesity therapeutics. Per the company, currently more than 20% of the U.S. population are considered clinically obese yet there remain few therapeutic option available. Harkness is performing exploratory human clinical trials in collaboration with the Pennington Institute in Louisiana.


ApoLife has developed platform yeast expression technologies for accelerated development of therapeutic antibodies (glycosylated and aglycosylated), antibody fragments, fusion proteins and antibodies and subunit vaccines through its Twin Cassette yeast system. ApoLife employs Bakers yeast (S.cerevisiae) which has been used for manufacturing several FDA approved therapeutic products thus giving ApoLife a competitive regulatory advantage over companies using other yeast systems. ApoLife's platform has the capability to make fully functional secreted antibodies and has potential to improve antibody potency. The technology has the capability to accelerate the process of identifying and selecting antibodies for target antigens, reducing the cost and development time by up to 50% of the current process.ApoLife uses its technology to develop anticancer antibodies and immunotoxins with collaborating partners.As a licensing partner, ApoLife has vectors, yeast strains, and production process available for antibody and biogeneric product development.


Neuronyx is focused on developing biomedicines by harnessing the therapeutic potential of the human cell.

InteKrin Therapeutics

InteKrin Therapeutics, Inc. is a privately-held clinical stage biopharmaceutical company based in Los Altos, California developing therapeutics for diabetes, obesity and metabolic disorders. The company was founded in 2005 by Denny Lanfear, a former Vice President and Officer of Amgen, and clinical endocrinologist Christos Mantzoros, M.D., DSc, FACP, FACE, Associate Professor of Medicine at Harvard Medical School. InteKrin's Scientific Advisory Board includes veterans from several successful biopharma organizations, internationally recognized experts in nuclear receptors and metabolism as well as top scientists formerly with the Food and Drug Administration. Its lead product, INT131, is a novel SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator) which is in Phase II clinical trials for diabetes. The company focuses on high value therapeutics in addressing unmet medical needs. To learn more about InteKrin, visit

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.